223 related articles for article (PubMed ID: 36679922)
1. A Monovalent Mt10-CVB3 Vaccine Prevents CVB4-Accelerated Type 1 Diabetes in NOD Mice.
Rasquinha MT; Lasrado N; Sur M; Mone K; Qiu H; Riethoven JJ; Sobel RA; Reddy J
Vaccines (Basel); 2022 Dec; 11(1):. PubMed ID: 36679922
[TBL] [Abstract][Full Text] [Related]
2. Mt10-CVB3 Vaccine Virus Protects against CVB4 Infection by Inducing Cross-Reactive, Antigen-Specific Immune Responses.
Lasrado N; Arumugam R; Rasquinha MT; Sur M; Steffen D; Reddy J
Microorganisms; 2021 Nov; 9(11):. PubMed ID: 34835449
[TBL] [Abstract][Full Text] [Related]
3. Mt10 Vaccine Protects Diversity Outbred Mice from CVB3 Infection by Producing Virus-Specific Neutralizing Antibodies and Diverse Antibody Isotypes.
Rasquinha MT; Mone K; Sur M; Lasrado N; Massilamany C; Kachman SD; Steffen D; Reddy J
Vaccines (Basel); 2024 Mar; 12(3):. PubMed ID: 38543901
[TBL] [Abstract][Full Text] [Related]
4. Toward testing the hypothesis that group B coxsackieviruses (CVB) trigger insulin-dependent diabetes: inoculating nonobese diabetic mice with CVB markedly lowers diabetes incidence.
Tracy S; Drescher KM; Chapman NM; Kim KS; Carson SD; Pirruccello S; Lane PH; Romero JR; Leser JS
J Virol; 2002 Dec; 76(23):12097-111. PubMed ID: 12414951
[TBL] [Abstract][Full Text] [Related]
5. Coxsackievirus B3 infection and type 1 diabetes development in NOD mice: insulitis determines susceptibility of pancreatic islets to virus infection.
Drescher KM; Kono K; Bopegamage S; Carson SD; Tracy S
Virology; 2004 Nov; 329(2):381-94. PubMed ID: 15518817
[TBL] [Abstract][Full Text] [Related]
6. Attenuated strain of CVB3 with a mutation in the CAR-interacting region protects against both myocarditis and pancreatitis.
Lasrado N; Gangaplara A; Massilamany C; Arumugam R; Shelbourn A; Rasquinha MT; Basavalingappa RH; Delhon G; Xiang SH; Pattnaik AK; Steffen D; Reddy J
Sci Rep; 2021 Jun; 11(1):12432. PubMed ID: 34127684
[TBL] [Abstract][Full Text] [Related]
7. Coxsackievirus B Vaccines Prevent Infection-Accelerated Diabetes in NOD Mice and Have No Disease-Inducing Effect.
Stone VM; Butrym M; Hankaniemi MM; Sioofy-Khojine AB; Hytönen VP; Hyöty H; Flodström-Tullberg M
Diabetes; 2021 Dec; 70(12):2871-2878. PubMed ID: 34497136
[TBL] [Abstract][Full Text] [Related]
8. Neutralizing activity induced by the attenuated coxsackievirus B3 Sabin3-like strain against CVB3 infection.
Jrad-Battikh N; Souii A; Oueslati L; Aouni M; Hober D; Gharbi J; Ben M'hadheb-Gharbi M
Curr Microbiol; 2014 Apr; 68(4):503-9. PubMed ID: 24322405
[TBL] [Abstract][Full Text] [Related]
9. Toll-like receptor 3 is critical for coxsackievirus B4-induced type 1 diabetes in female NOD mice.
McCall KD; Thuma JR; Courreges MC; Benencia F; James CB; Malgor R; Kantake N; Mudd W; Denlinger N; Nolan B; Wen L; Schwartz FL
Endocrinology; 2015 Feb; 156(2):453-61. PubMed ID: 25422874
[TBL] [Abstract][Full Text] [Related]
10. Mapping of a neutralizing antigenic site of Coxsackievirus B4 by construction of an antigen chimera.
Reimann BY; Zell R; Kandolf R
J Virol; 1991 Jul; 65(7):3475-80. PubMed ID: 1645779
[TBL] [Abstract][Full Text] [Related]
11. Oral immunization with a live coxsackievirus/HIV recombinant induces gag p24-specific T cell responses.
Gu R; Shampang A; Nashar T; Patil M; Fuller DH; Ramsingh AI
PLoS One; 2010 Sep; 5(9):. PubMed ID: 20824074
[TBL] [Abstract][Full Text] [Related]
12. Coxsackievirus B4 Exposure Results in Variable Pattern Recognition Response in the Kidneys of Female Non-Obese Diabetic Mice Before Establishment of Diabetes.
Walter DL; Benner SE; Oaks RJ; Thuma JR; Malgor R; Schwartz FL; Coschigano KT; McCall KD
Viral Immunol; 2020 Sep; 33(7):494-506. PubMed ID: 32352894
[TBL] [Abstract][Full Text] [Related]
13. A hexavalent Coxsackievirus B vaccine is highly immunogenic and has a strong protective capacity in mice and nonhuman primates.
Stone VM; Hankaniemi MM; Laitinen OH; Sioofy-Khojine AB; Lin A; Diaz Lozano IM; Mazur MA; Marjomäki V; Loré K; Hyöty H; Hytönen VP; Flodström-Tullberg M
Sci Adv; 2020 May; 6(19):eaaz2433. PubMed ID: 32494709
[TBL] [Abstract][Full Text] [Related]
14. Multiple subtypes of coxsackievirus group B can cause congenital heart disease.
Sharma V; Goessling LS; Brar AK; Eghtesady P
Birth Defects Res; 2023 Jan; 115(2):171-178. PubMed ID: 36094067
[TBL] [Abstract][Full Text] [Related]
15. Vaccines against Group B Coxsackieviruses and Their Importance.
Mone K; Lasrado N; Sur M; Reddy J
Vaccines (Basel); 2023 Jan; 11(2):. PubMed ID: 36851152
[TBL] [Abstract][Full Text] [Related]
16. Viral Protein VP1 Virus-like Particles (VLP) of CVB4 Induces Protective Immunity against Lethal Challenges with Diabetogenic E2 and Wild Type JBV Strains in Mice Model.
Gharbi J; Hadj Hassine I; Hassine M; Al-Malki M; Al-Yami A; Al-Bachir A; Ben M'hadheb M
Viruses; 2023 Mar; 15(4):. PubMed ID: 37112858
[TBL] [Abstract][Full Text] [Related]
17. Viral protein VP4 is a target of human antibodies enhancing coxsackievirus B4- and B3-induced synthesis of alpha interferon.
Chehadeh W; Lobert PE; Sauter P; Goffard A; Lucas B; Weill J; Vantyghem MC; Alm G; Pigny P; Hober D
J Virol; 2005 Nov; 79(22):13882-91. PubMed ID: 16254324
[TBL] [Abstract][Full Text] [Related]
18. Diabetes acceleration or prevention by a coxsackievirus B4 infection: critical requirements for both interleukin-4 and gamma interferon.
Serreze DV; Wasserfall C; Ottendorfer EW; Stalvey M; Pierce MA; Gauntt C; O'Donnell B; Flanagan JB; Campbell-Thompson M; Ellis TM; Atkinson MA
J Virol; 2005 Jan; 79(2):1045-52. PubMed ID: 15613333
[TBL] [Abstract][Full Text] [Related]
19. Expression of an antigenic adenovirus epitope in a group B coxsackievirus.
Höfling K; Tracy S; Chapman N; Kim KS; Smith Leser J
J Virol; 2000 May; 74(10):4570-8. PubMed ID: 10775593
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and protective efficacy of inactivated coxsackievirus B4 viral particles.
Wang T; Wang C; Pang L; Zhang Y; Wang S; Liang X; Huang Z
Emerg Microbes Infect; 2024 Dec; 13(1):2337665. PubMed ID: 38551145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
